Special Issue "Pharmacotherapy during Pregnancy, Childbirth and Lactation"

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Women's Health".

Deadline for manuscript submissions: 30 April 2022.

Special Issue Editor

Prof. Dr. Karel Allegaert
E-Mail Website
Guest Editor
1. Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium
2. Woman and Child, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium
3. Department of Clinical Pharmacy, Erasmus MC Sophia Children’s Hospital, 3000 CA Rotterdam, The Netherlands
Interests: perinatal pharmacology; developmental pharmacology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pharmacotherapy is a very powerful tool to improve the medical outcome of pregnant women and their newborns. As little as 5% of available drugs have been properly monitored, tested and labeled for use in pregnancy and lactation. Pregnant or lactating women are usually excluded from clinical trials, while product development for diseases specific to pregnancy or perinatal indications is very limited. However, in real life, pregnant women get ill, and ill women get pregnant. Pregnant or lactating women and their caregivers are left in the dark about risks they cannot oversee, and they need to take responsibility for this uncertainty.

This Special Issue on perinatal clinical pharmacology aims to focus on various methods that can be applied and tailored to pregnancy and lactation, including but not limited to pharmacokinetic modeling, pharmaco-epidemiology, in vitro models (such as placental transfer), lactation and pharmacovigilance. Papers on pharmacotherapy on diseases related to pregnancy (preterm labor, pre-eclampsia, fetal anomalies, postpartum hemorrhage) and diseases that occur during pregnancy (depression, oncological diseases, peri-operative care, infectious diseases) are very welcome.

Prof. Dr. Karel Allegaert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacovigilance
  • pharmaco-epidemiology
  • pharmacokinetics
  • lactation, childbirth
  • pregnancy

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Article
Development and Pilot Use of a Questionnaire to Assess the Knowledge of Midwives and Pediatric Nurses on Maternal Use of Analgesics during Lactation
Int. J. Environ. Res. Public Health 2021, 18(21), 11555; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph182111555 - 03 Nov 2021
Viewed by 563
Abstract
There is a need to assess the knowledge of healthcare providers on the use of maternal analgesics during lactation; however, valid instruments are not yet available. This study aimed to develop and test a valid questionnaire on the knowledge of analgesics (acetaminophen, ibuprofen, [...] Read more.
There is a need to assess the knowledge of healthcare providers on the use of maternal analgesics during lactation; however, valid instruments are not yet available. This study aimed to develop and test a valid questionnaire on the knowledge of analgesics (acetaminophen, ibuprofen, aspirin, tramadol, codeine, oxycodone) during lactation, using a structured, stepwise approach. As a first step, literature was screened to generate a preliminary version consisting of a pool of item subgroups. This preliminary version was subsequently reviewed during two focus groups (midwives: n = 4; pediatric nurses: n = 6), followed by a two-round online Delphi with experts (n = 7) to confirm item and scale content validity. This resulted in an instrument consisting of 33 questions and 5 specific clinical case descriptions for both disciplines. Based on the assumption of an a priori difference in knowledge between midwives and pediatric nurses related to their curricula (known-groups validity), high construct validity was demonstrated in a pilot survey (midwives: n = 86; pediatric nurses: n = 73). We therefore conclude that a valid instrument to assess knowledge on lactation-related exposure to analgesics was generated, which could be further validated and used for research and educational purposes. As these pilot findings suggest suboptimal knowledge for both professions on this topic, adaptations to their curricula and postgraduate training might be warranted. Full article
(This article belongs to the Special Issue Pharmacotherapy during Pregnancy, Childbirth and Lactation)
Show Figures

Figure 1

Review

Jump to: Research

Review
The Function of the Kynurenine Pathway in the Placenta: A Novel Pharmacotherapeutic Target?
Int. J. Environ. Res. Public Health 2021, 18(21), 11545; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph182111545 - 03 Nov 2021
Viewed by 445
Abstract
(L-)tryptophan is metabolized via the kynurenine pathway into several kynurenine metabolites with distinct functions. Dysfunction of the kynurenine pathway can lead to impairments in vascular regulation, immune regulation, and tolerance. The first and rate limiting enzyme of this pathway, indoleamine 2,3-dioxygenase [...] Read more.
(L-)tryptophan is metabolized via the kynurenine pathway into several kynurenine metabolites with distinct functions. Dysfunction of the kynurenine pathway can lead to impairments in vascular regulation, immune regulation, and tolerance. The first and rate limiting enzyme of this pathway, indoleamine 2,3-dioxygenase (IDO), is highly expressed in the placenta and reduced in placentas from complicated pregnancies. IDO is essential during pregnancy, as IDO inhibition in pregnant mice resulted in fetal loss. However, the exact function of placental IDO, as well as its exact placental localization, remain controversial. This review identified that two isoforms of IDO; IDO1 and IDO2, are differently expressed between placental cells, suggesting spatial segregation. Furthermore, this review summarizes how the placental kynurenine pathway is altered in pregnancy complications, including recurrent miscarriage, preterm birth, preeclampsia, and fetal growth restriction. Importantly, we describe that these alterations do not affect maternally circulating metabolite concentrations, suggesting that the kynurenine pathway functions as a local signaling pathway. In the placenta, it is an important source of de novo placental NAD+ synthesis and regulates fetal tryptophan and kynurenine metabolite supply. Therefore, kynurenine pathway interventions might provide opportunities to treat pregnancy complications, and this review discusses how such treatment could affect placental function and pregnancy development. Full article
(This article belongs to the Special Issue Pharmacotherapy during Pregnancy, Childbirth and Lactation)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Sildenafil during pregnancy: trials and tribulations
Authors: De Bie Felix
Affiliation: Philadelphia, United States

Title: Perinatal medicines’ information needs and counseling preferences of potential TIS users in Belgium: results from a cross-sectional study among patients and healthcare professionals
Authors: Michael Ceulemans
Affiliation: KU Leuven, Belgium

Title: The placental kynurenine pathway as therapeutic target during pregnacy
Authors: Michelle Broekhuizen
Affiliation: Rotterdam, the Netherlands

Title: lithium use during pregnancy and a postnatal clinical protocol
Authors: Anne Smits
Affiliation: UZ Leuven, Belgium

Title: Effects of maternal β-blockeruse on neonatal outcome
Authors: Vandenbosch Gerbrich
Affiliation: Rotterdam, the Netherlands

Back to TopTop